Post-COVID complications Infections and Infestations
Conditions
Interventions
The aim of this pilot control clinical trial is to investigate the effect of neurofeedback therapy (Othmer method) on fatigue, anxiety, and depression after COVID-19. For measuring the severity of pos
Sponsors
Charles University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years 2. A positive history of SARS-CoV-2 infection confirmed by a positive antigen/reverse transcription polymerase chain reaction (RT-PCR)/antibody test 3. At least one of the following symptoms: insomnia, headaches/migraines, dizziness, seizures, fatigue, depression, and anxiety that were not present prior to SARS-CoV-2 infection 4. The specific symptoms should have been present or persisted for at least 3 months after confirmed SARS-CoV-2 infection and should not have been attributable to any other neurological disease prior to COVID-19 5. Being free of neurological/systemic health problems prior to SARS-CoV-2 6. Being medication-free (or medically stable in type and dosage of the drug for at least 3 months prior to neurofeedback experiment)
Exclusion criteria
Exclusion criteria: 1. Younger than 18 years 2. No positive anamnesis of SARS-CoV-2 infection confirmed by positive antigen/RT-PCR/antibody test 3. Absence of post-COVID complications 4. The presence of neurological/systemic disorders prior to SARS-CoV-2 infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Fatigue measured using the Fatigue Assessment Scale at baseline, immediately, 1 week and 1 month after neurofeedback 2. Anxiety measured using the Beck Anxiety Inventory at baseline, immediately, 1 week and 1 month after neurofeedback 3. Depression measured using the Beck Depression Inventory (version 2) at baseline, immediately, 1 week and 1 month after neurofeedback 4. Dizziness measured using the Dizziness Handicap Inventory at baseline, immediately, 1 week and 1 month after neurofeedback 5. Seizures are measured using the Seizure Severity Questionnaire at baseline, immediately, 1 week and 1 month after neurofeedback 6. Migraines/headaches measured using the Headache Disability Index at baseline, immediately, 1 week and 1 month after neurofeedback 7. Insomnia measured using the Insomnia Severity Index at baseline, immediately, 1 week and 1 month after neurofeedback | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using Visual Analogue Scales at baseline, immediately, one week and one month after neurofeedback: 1. Mood swings 2. Memory and attention problems | — |
Countries
Czech Republic
Contacts
Public ContactMária Orendácová
Outcome results
None listed